nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludrocortisone—AR—oviduct—ovarian cancer	0.0305	0.124	CbGeAlD
Fludrocortisone—Cutaneous hypersensitivity—Chlorambucil—ovarian cancer	0.0241	0.0522	CcSEcCtD
Fludrocortisone—Muscle atrophy—Melphalan—ovarian cancer	0.0218	0.0471	CcSEcCtD
Fludrocortisone—Cutaneous hypersensitivity—Melphalan—ovarian cancer	0.021	0.0455	CcSEcCtD
Fludrocortisone—Neoplasm—Altretamine—ovarian cancer	0.015	0.0324	CcSEcCtD
Fludrocortisone—NR3C2—Nuclear Receptor transcription pathway—NR5A1—ovarian cancer	0.0137	0.0515	CbGpPWpGaD
Fludrocortisone—AR—Regulation of Androgen receptor activity—SPDEF—ovarian cancer	0.0135	0.0505	CbGpPWpGaD
Fludrocortisone—NR3C2—myometrium—ovarian cancer	0.0132	0.0537	CbGeAlD
Fludrocortisone—Impaired healing—Melphalan—ovarian cancer	0.0119	0.0257	CcSEcCtD
Fludrocortisone—NR3C2—Preimplantation Embryo—AQP3—ovarian cancer	0.0112	0.0421	CbGpPWpGaD
Fludrocortisone—Cutaneous hypersensitivity—Docetaxel—ovarian cancer	0.0105	0.0227	CcSEcCtD
Fludrocortisone—NR3C2—uterine cervix—ovarian cancer	0.0102	0.0418	CbGeAlD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—SPDEF—ovarian cancer	0.0102	0.0383	CbGpPWpGaD
Fludrocortisone—AR—myometrium—ovarian cancer	0.00975	0.0398	CbGeAlD
Fludrocortisone—NR3C2—endometrium—ovarian cancer	0.00927	0.0378	CbGeAlD
Fludrocortisone—NR3C2—uterus—ovarian cancer	0.00854	0.0348	CbGeAlD
Fludrocortisone—AR—Nuclear Receptors—NR5A1—ovarian cancer	0.00807	0.0303	CbGpPWpGaD
Fludrocortisone—Dermatitis atopic—Chlorambucil—ovarian cancer	0.00794	0.0172	CcSEcCtD
Fludrocortisone—NR3C2—female reproductive system—ovarian cancer	0.00768	0.0313	CbGeAlD
Fludrocortisone—AR—epithelium—ovarian cancer	0.00765	0.0312	CbGeAlD
Fludrocortisone—AR—uterine cervix—ovarian cancer	0.00759	0.0309	CbGeAlD
Fludrocortisone—AR—decidua—ovarian cancer	0.00723	0.0295	CbGeAlD
Fludrocortisone—NR3C1—myometrium—ovarian cancer	0.00706	0.0288	CbGeAlD
Fludrocortisone—NR3C2—female gonad—ovarian cancer	0.00699	0.0285	CbGeAlD
Fludrocortisone—NR3C2—vagina—ovarian cancer	0.00694	0.0283	CbGeAlD
Fludrocortisone—Dermatitis atopic—Melphalan—ovarian cancer	0.00693	0.015	CcSEcCtD
Fludrocortisone—AR—endometrium—ovarian cancer	0.00686	0.028	CbGeAlD
Fludrocortisone—NR3C2—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.00684	0.0257	CbGpPWpGaD
Fludrocortisone—NR3C1—embryo—ovarian cancer	0.00679	0.0277	CbGeAlD
Fludrocortisone—NR3C2—Preimplantation Embryo—SMARCA4—ovarian cancer	0.00675	0.0253	CbGpPWpGaD
Fludrocortisone—Amenorrhoea—Chlorambucil—ovarian cancer	0.00669	0.0145	CcSEcCtD
Fludrocortisone—Vertigo—Altretamine—ovarian cancer	0.0065	0.0141	CcSEcCtD
Fludrocortisone—AR—Nuclear Receptor transcription pathway—NR5A1—ovarian cancer	0.00638	0.0239	CbGpPWpGaD
Fludrocortisone—AR—gonad—ovarian cancer	0.00637	0.026	CbGeAlD
Fludrocortisone—AR—uterus—ovarian cancer	0.00632	0.0258	CbGeAlD
Fludrocortisone—Convulsion—Altretamine—ovarian cancer	0.00627	0.0136	CcSEcCtD
Fludrocortisone—NR3C2—testis—ovarian cancer	0.0062	0.0253	CbGeAlD
Fludrocortisone—NR3C1—Nuclear Receptors—NR5A1—ovarian cancer	0.00612	0.023	CbGpPWpGaD
Fludrocortisone—Amenorrhoea—Melphalan—ovarian cancer	0.00583	0.0126	CcSEcCtD
Fludrocortisone—AR—female reproductive system—ovarian cancer	0.00569	0.0232	CbGeAlD
Fludrocortisone—NR3C1—epithelium—ovarian cancer	0.00554	0.0226	CbGeAlD
Fludrocortisone—NR3C1—uterine cervix—ovarian cancer	0.0055	0.0224	CbGeAlD
Fludrocortisone—Neoplasm—Chlorambucil—ovarian cancer	0.00532	0.0115	CcSEcCtD
Fludrocortisone—Dydrogesterone—PGR—ovarian cancer	0.0053	0.198	CrCbGaD
Fludrocortisone—NR3C1—decidua—ovarian cancer	0.00524	0.0214	CbGeAlD
Fludrocortisone—AR—female gonad—ovarian cancer	0.00517	0.0211	CbGeAlD
Fludrocortisone—AR—vagina—ovarian cancer	0.00514	0.021	CbGeAlD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—BCL9—ovarian cancer	0.00509	0.0191	CbGpPWpGaD
Fludrocortisone—Skin hyperpigmentation—Paclitaxel—ovarian cancer	0.00506	0.011	CcSEcCtD
Fludrocortisone—NR3C1—endometrium—ovarian cancer	0.00497	0.0203	CbGeAlD
Fludrocortisone—NR3C1—Nuclear Receptor transcription pathway—NR5A1—ovarian cancer	0.00484	0.0181	CbGpPWpGaD
Fludrocortisone—Rash maculo-papular—Topotecan—ovarian cancer	0.00476	0.0103	CcSEcCtD
Fludrocortisone—Neoplasm—Topotecan—ovarian cancer	0.00473	0.0103	CcSEcCtD
Fludrocortisone—Cardiomegaly—Epirubicin—ovarian cancer	0.00472	0.0102	CcSEcCtD
Fludrocortisone—Neoplasm—Melphalan—ovarian cancer	0.00463	0.01	CcSEcCtD
Fludrocortisone—Menstruation irregular—Docetaxel—ovarian cancer	0.00461	0.00999	CcSEcCtD
Fludrocortisone—NR3C1—gonad—ovarian cancer	0.00461	0.0188	CbGeAlD
Fludrocortisone—AR—testis—ovarian cancer	0.00459	0.0187	CbGeAlD
Fludrocortisone—NR3C1—uterus—ovarian cancer	0.00458	0.0187	CbGeAlD
Fludrocortisone—NR3C2—lymph node—ovarian cancer	0.00449	0.0183	CbGeAlD
Fludrocortisone—Cardiomegaly—Doxorubicin—ovarian cancer	0.00437	0.00946	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Docetaxel—ovarian cancer	0.00429	0.0093	CcSEcCtD
Fludrocortisone—Asthenia—Altretamine—ovarian cancer	0.00424	0.00918	CcSEcCtD
Fludrocortisone—NR3C1—female reproductive system—ovarian cancer	0.00412	0.0168	CbGeAlD
Fludrocortisone—Oesophagitis—Vinorelbine—ovarian cancer	0.00409	0.00887	CcSEcCtD
Fludrocortisone—Dermatitis atopic—Paclitaxel—ovarian cancer	0.00407	0.00882	CcSEcCtD
Fludrocortisone—Infection—Carboplatin—ovarian cancer	0.00405	0.00878	CcSEcCtD
Fludrocortisone—AR—Nuclear Receptors—PGR—ovarian cancer	0.00402	0.0151	CbGpPWpGaD
Fludrocortisone—NR3C1—Signaling events mediated by HDAC Class II—HDAC6—ovarian cancer	0.00394	0.0148	CbGpPWpGaD
Fludrocortisone—Anaphylactoid reaction—Topotecan—ovarian cancer	0.00393	0.00851	CcSEcCtD
Fludrocortisone—NR3C1—bone marrow—ovarian cancer	0.00389	0.0159	CbGeAlD
Fludrocortisone—Thrombophlebitis—Vinorelbine—ovarian cancer	0.00376	0.00814	CcSEcCtD
Fludrocortisone—NR3C1—female gonad—ovarian cancer	0.00375	0.0153	CbGeAlD
Fludrocortisone—NR3C1—vagina—ovarian cancer	0.00372	0.0152	CbGeAlD
Fludrocortisone—NR3C2—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.00365	0.0137	CbGpPWpGaD
Fludrocortisone—Contusion—Paclitaxel—ovarian cancer	0.00345	0.00748	CcSEcCtD
Fludrocortisone—Dermatitis atopic—Docetaxel—ovarian cancer	0.00345	0.00748	CcSEcCtD
Fludrocortisone—AR—lymph node—ovarian cancer	0.00333	0.0136	CbGeAlD
Fludrocortisone—NR3C1—testis—ovarian cancer	0.00332	0.0136	CbGeAlD
Fludrocortisone—Hypernatraemia—Epirubicin—ovarian cancer	0.00328	0.0071	CcSEcCtD
Fludrocortisone—Megestrol acetate—PGR—ovarian cancer	0.00319	0.119	CrCbGaD
Fludrocortisone—AR—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.00318	0.0119	CbGpPWpGaD
Fludrocortisone—AR—Notch-mediated HES/HEY network—PARP1—ovarian cancer	0.00315	0.0118	CbGpPWpGaD
Fludrocortisone—NR3C1—Nuclear Receptors—PGR—ovarian cancer	0.00305	0.0114	CbGpPWpGaD
Fludrocortisone—Hypernatraemia—Doxorubicin—ovarian cancer	0.00303	0.00657	CcSEcCtD
Fludrocortisone—Amenorrhoea—Docetaxel—ovarian cancer	0.00291	0.0063	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Epirubicin—ovarian cancer	0.0029	0.00627	CcSEcCtD
Fludrocortisone—NR3C2—Preimplantation Embryo—CDH1—ovarian cancer	0.00287	0.0108	CbGpPWpGaD
Fludrocortisone—Muscular weakness—Vinorelbine—ovarian cancer	0.00287	0.00621	CcSEcCtD
Fludrocortisone—Fluid retention—Paclitaxel—ovarian cancer	0.00286	0.0062	CcSEcCtD
Fludrocortisone—AR—FOXA1 transcription factor network—BRCA1—ovarian cancer	0.00286	0.0107	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—BARD1—ovarian cancer	0.00285	0.0107	CbGpPWpGaD
Fludrocortisone—NR3C1—Endoderm Differentiation—HNF1B—ovarian cancer	0.00283	0.0106	CbGpPWpGaD
Fludrocortisone—Optic neuritis—Epirubicin—ovarian cancer	0.0028	0.00607	CcSEcCtD
Fludrocortisone—Pancreatitis—Vinorelbine—ovarian cancer	0.00275	0.00597	CcSEcCtD
Fludrocortisone—Oesophagitis—Paclitaxel—ovarian cancer	0.00275	0.00597	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Paclitaxel—ovarian cancer	0.00274	0.00593	CcSEcCtD
Fludrocortisone—Neoplasm—Paclitaxel—ovarian cancer	0.00272	0.0059	CcSEcCtD
Fludrocortisone—AR—FOXA1 transcription factor network—SOD1—ovarian cancer	0.00271	0.0102	CbGpPWpGaD
Fludrocortisone—Skin hyperpigmentation—Doxorubicin—ovarian cancer	0.00268	0.00581	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.00265	0.00992	CbGpPWpGaD
Fludrocortisone—Haemoglobin—Topotecan—ovarian cancer	0.00264	0.00573	CcSEcCtD
Fludrocortisone—Haemorrhage—Topotecan—ovarian cancer	0.00263	0.0057	CcSEcCtD
Fludrocortisone—Optic neuritis—Doxorubicin—ovarian cancer	0.00259	0.00561	CcSEcCtD
Fludrocortisone—Haemoglobin—Melphalan—ovarian cancer	0.00259	0.00561	CcSEcCtD
Fludrocortisone—Haemorrhage—Melphalan—ovarian cancer	0.00257	0.00558	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—ATF3—ovarian cancer	0.00255	0.00956	CbGpPWpGaD
Fludrocortisone—Thrombophlebitis—Paclitaxel—ovarian cancer	0.00253	0.00547	CcSEcCtD
Fludrocortisone—Fluid retention—Docetaxel—ovarian cancer	0.00242	0.00525	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—SMARCA4—ovarian cancer	0.00242	0.00908	CbGpPWpGaD
Fludrocortisone—Cardiac failure congestive—Paclitaxel—ovarian cancer	0.00241	0.00523	CcSEcCtD
Fludrocortisone—NR3C1—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.00241	0.00904	CbGpPWpGaD
Fludrocortisone—NR3C1—lymph node—ovarian cancer	0.00241	0.00982	CbGeAlD
Fludrocortisone—Injury—Paclitaxel—ovarian cancer	0.00238	0.00516	CcSEcCtD
Fludrocortisone—NR3C2—Generic Transcription Pathway—NR5A1—ovarian cancer	0.00237	0.0089	CbGpPWpGaD
Fludrocortisone—Oesophagitis—Docetaxel—ovarian cancer	0.00233	0.00506	CcSEcCtD
Fludrocortisone—Dermatitis atopic—Epirubicin—ovarian cancer	0.00233	0.00504	CcSEcCtD
Fludrocortisone—Neoplasm—Docetaxel—ovarian cancer	0.00231	0.005	CcSEcCtD
Fludrocortisone—Convulsion—Chlorambucil—ovarian cancer	0.00223	0.00483	CcSEcCtD
Fludrocortisone—AR—Coregulation of Androgen receptor activity—BRCA1—ovarian cancer	0.0022	0.00825	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—ATF3—ovarian cancer	0.00217	0.00815	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.00216	0.00809	CbGpPWpGaD
Fludrocortisone—Dermatitis atopic—Doxorubicin—ovarian cancer	0.00215	0.00467	CcSEcCtD
Fludrocortisone—AR—Nuclear Receptors—ESR1—ovarian cancer	0.00215	0.00805	CbGpPWpGaD
Fludrocortisone—Thrombophlebitis—Docetaxel—ovarian cancer	0.00214	0.00464	CcSEcCtD
Fludrocortisone—Glycosuria—Epirubicin—ovarian cancer	0.00213	0.00461	CcSEcCtD
Fludrocortisone—Petechiae—Epirubicin—ovarian cancer	0.00209	0.00454	CcSEcCtD
Fludrocortisone—Infection—Chlorambucil—ovarian cancer	0.00208	0.00452	CcSEcCtD
Fludrocortisone—Mood swings—Paclitaxel—ovarian cancer	0.00207	0.00449	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Docetaxel—ovarian cancer	0.00204	0.00443	CcSEcCtD
Fludrocortisone—Spironolactone—PGR—ovarian cancer	0.00198	0.074	CrCbGaD
Fludrocortisone—Glycosuria—Doxorubicin—ovarian cancer	0.00197	0.00426	CcSEcCtD
Fludrocortisone—Amenorrhoea—Epirubicin—ovarian cancer	0.00196	0.00425	CcSEcCtD
Fludrocortisone—Erythema—Vinorelbine—ovarian cancer	0.00196	0.00424	CcSEcCtD
Fludrocortisone—Myalgia—Topotecan—ovarian cancer	0.00195	0.00422	CcSEcCtD
Fludrocortisone—Convulsion—Melphalan—ovarian cancer	0.00194	0.00421	CcSEcCtD
Fludrocortisone—Petechiae—Doxorubicin—ovarian cancer	0.00194	0.0042	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ATF3—ovarian cancer	0.00193	0.00725	CbGpPWpGaD
Fludrocortisone—Muscular weakness—Paclitaxel—ovarian cancer	0.00193	0.00418	CcSEcCtD
Fludrocortisone—AR—FOXA1 transcription factor network—ESR1—ovarian cancer	0.00191	0.00716	CbGpPWpGaD
Fludrocortisone—Myalgia—Melphalan—ovarian cancer	0.00191	0.00413	CcSEcCtD
Fludrocortisone—Abdominal distension—Paclitaxel—ovarian cancer	0.0019	0.00412	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Topotecan—ovarian cancer	0.00187	0.00405	CcSEcCtD
Fludrocortisone—Medroxyprogesterone Acetate—PGR—ovarian cancer	0.00186	0.0693	CrCbGaD
Fludrocortisone—Infection—Topotecan—ovarian cancer	0.00186	0.00402	CcSEcCtD
Fludrocortisone—Pancreatitis—Paclitaxel—ovarian cancer	0.00185	0.00402	CcSEcCtD
Fludrocortisone—Sweating increased—Paclitaxel—ovarian cancer	0.00184	0.00399	CcSEcCtD
Fludrocortisone—Oedema—Melphalan—ovarian cancer	0.00183	0.00396	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Melphalan—ovarian cancer	0.00183	0.00396	CcSEcCtD
Fludrocortisone—Infection—Melphalan—ovarian cancer	0.00182	0.00394	CcSEcCtD
Fludrocortisone—Amenorrhoea—Doxorubicin—ovarian cancer	0.00181	0.00393	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Topotecan—ovarian cancer	0.00181	0.00391	CcSEcCtD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—SMARCA4—ovarian cancer	0.0018	0.00676	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—RBL2—ovarian cancer	0.00179	0.0067	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND2—ovarian cancer	0.00177	0.00664	CbGpPWpGaD
Fludrocortisone—Vertigo—Vinorelbine—ovarian cancer	0.00176	0.00381	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Paclitaxel—ovarian cancer	0.0017	0.00369	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.0017	0.00369	CcSEcCtD
Fludrocortisone—AR—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.0017	0.00636	CbGpPWpGaD
Fludrocortisone—Hypertension—Vinorelbine—ovarian cancer	0.00169	0.00366	CcSEcCtD
Fludrocortisone—Betamethasone—PGR—ovarian cancer	0.00169	0.063	CrCbGaD
Fludrocortisone—Urticaria—Chlorambucil—ovarian cancer	0.00167	0.00361	CcSEcCtD
Fludrocortisone—Myalgia—Vinorelbine—ovarian cancer	0.00167	0.00361	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00167	0.00361	CcSEcCtD
Fludrocortisone—Fluid retention—Epirubicin—ovarian cancer	0.00163	0.00354	CcSEcCtD
Fludrocortisone—NR3C1—Nuclear Receptors—ESR1—ovarian cancer	0.00163	0.00611	CbGpPWpGaD
Fludrocortisone—NR3C1—Signaling events mediated by HDAC Class II—ESR1—ovarian cancer	0.00163	0.00611	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—BRCA1—ovarian cancer	0.00163	0.0061	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—WDR77—ovarian cancer	0.0016	0.00602	CbGpPWpGaD
Fludrocortisone—Anaphylactic shock—Vinorelbine—ovarian cancer	0.0016	0.00346	CcSEcCtD
Fludrocortisone—Infection—Vinorelbine—ovarian cancer	0.00159	0.00344	CcSEcCtD
Fludrocortisone—Oesophagitis—Epirubicin—ovarian cancer	0.00157	0.00341	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Epirubicin—ovarian cancer	0.00157	0.00339	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MSH2—ovarian cancer	0.00156	0.00585	CbGpPWpGaD
Fludrocortisone—Ecchymosis—Epirubicin—ovarian cancer	0.00156	0.00337	CcSEcCtD
Fludrocortisone—Neoplasm—Epirubicin—ovarian cancer	0.00156	0.00337	CcSEcCtD
Fludrocortisone—Hypersensitivity—Chlorambucil—ovarian cancer	0.00155	0.00335	CcSEcCtD
Fludrocortisone—Haemoglobin—Paclitaxel—ovarian cancer	0.00152	0.00329	CcSEcCtD
Fludrocortisone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—ovarian cancer	0.00152	0.00568	CbGpPWpGaD
Fludrocortisone—Fluid retention—Doxorubicin—ovarian cancer	0.00151	0.00328	CcSEcCtD
Fludrocortisone—Haemorrhage—Paclitaxel—ovarian cancer	0.00151	0.00328	CcSEcCtD
Fludrocortisone—Asthenia—Chlorambucil—ovarian cancer	0.00151	0.00326	CcSEcCtD
Fludrocortisone—Urticaria—Topotecan—ovarian cancer	0.00148	0.00322	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—SMARCA4—ovarian cancer	0.00146	0.00546	CbGpPWpGaD
Fludrocortisone—Oesophagitis—Doxorubicin—ovarian cancer	0.00146	0.00316	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00146	0.00315	CcSEcCtD
Fludrocortisone—Urticaria—Melphalan—ovarian cancer	0.00145	0.00315	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Doxorubicin—ovarian cancer	0.00145	0.00314	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Epirubicin—ovarian cancer	0.00144	0.00313	CcSEcCtD
Fludrocortisone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK1—ovarian cancer	0.00144	0.00541	CbGpPWpGaD
Fludrocortisone—Ecchymosis—Doxorubicin—ovarian cancer	0.00144	0.00312	CcSEcCtD
Fludrocortisone—Neoplasm—Doxorubicin—ovarian cancer	0.00144	0.00312	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Epirubicin—ovarian cancer	0.00144	0.00311	CcSEcCtD
Fludrocortisone—AR—Androgen receptor signaling pathway—CCNE1—ovarian cancer	0.00142	0.00534	CbGpPWpGaD
Fludrocortisone—Vascular purpura—Epirubicin—ovarian cancer	0.0014	0.00303	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Epirubicin—ovarian cancer	0.00138	0.00299	CcSEcCtD
Fludrocortisone—Hypersensitivity—Topotecan—ovarian cancer	0.00138	0.00298	CcSEcCtD
Fludrocortisone—Fluoxymesterone—ESR1—ovarian cancer	0.00137	0.051	CrCbGaD
Fludrocortisone—NR3C2—Generic Transcription Pathway—YAP1—ovarian cancer	0.00135	0.00508	CbGpPWpGaD
Fludrocortisone—AR—Nongenotropic Androgen signaling—MAPK3—ovarian cancer	0.00135	0.00506	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Melphalan—ovarian cancer	0.00135	0.00292	CcSEcCtD
Fludrocortisone—Asthenia—Topotecan—ovarian cancer	0.00134	0.0029	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Doxorubicin—ovarian cancer	0.00134	0.0029	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Doxorubicin—ovarian cancer	0.00133	0.00288	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—ovarian cancer	0.00133	0.00498	CbGpPWpGaD
Fludrocortisone—Erythema—Paclitaxel—ovarian cancer	0.00132	0.00285	CcSEcCtD
Fludrocortisone—Asthenia—Melphalan—ovarian cancer	0.00131	0.00284	CcSEcCtD
Fludrocortisone—AR—FOXA1 transcription factor network—CDKN1B—ovarian cancer	0.0013	0.00486	CbGpPWpGaD
Fludrocortisone—Purpura—Epirubicin—ovarian cancer	0.0013	0.00281	CcSEcCtD
Fludrocortisone—Vascular purpura—Doxorubicin—ovarian cancer	0.00129	0.0028	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.00129	0.0028	CcSEcCtD
Fludrocortisone—Haemoglobin—Docetaxel—ovarian cancer	0.00129	0.00279	CcSEcCtD
Fludrocortisone—NR3C1—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.00129	0.00482	CbGpPWpGaD
Fludrocortisone—AR—Nongenotropic Androgen signaling—MAPK1—ovarian cancer	0.00128	0.00482	CbGpPWpGaD
Fludrocortisone—Haemorrhage—Docetaxel—ovarian cancer	0.00128	0.00278	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.00128	0.00276	CcSEcCtD
Fludrocortisone—Urticaria—Vinorelbine—ovarian cancer	0.00127	0.00275	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—TTF1—ovarian cancer	0.00126	0.00472	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—GADD45A—ovarian cancer	0.00124	0.00467	CbGpPWpGaD
Fludrocortisone—AR—Notch-mediated HES/HEY network—CDKN1B—ovarian cancer	0.00123	0.00461	CbGpPWpGaD
Fludrocortisone—Affect lability—Epirubicin—ovarian cancer	0.00123	0.00267	CcSEcCtD
Fludrocortisone—Purpura—Doxorubicin—ovarian cancer	0.0012	0.0026	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.0012	0.00259	CcSEcCtD
Fludrocortisone—Mood swings—Epirubicin—ovarian cancer	0.00118	0.00257	CcSEcCtD
Fludrocortisone—Vertigo—Paclitaxel—ovarian cancer	0.00118	0.00256	CcSEcCtD
Fludrocortisone—NR3C2—Generic Transcription Pathway—PGR—ovarian cancer	0.00118	0.00443	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Vinorelbine—ovarian cancer	0.00118	0.00255	CcSEcCtD
Fludrocortisone—Medroxyprogesterone Acetate—ESR1—ovarian cancer	0.00117	0.0438	CrCbGaD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—ovarian cancer	0.00117	0.00439	CbGpPWpGaD
Fludrocortisone—Headache—Topotecan—ovarian cancer	0.00117	0.00254	CcSEcCtD
Fludrocortisone—Asthenia—Vinorelbine—ovarian cancer	0.00115	0.00248	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—NR5A1—ovarian cancer	0.00114	0.00429	CbGpPWpGaD
Fludrocortisone—Convulsion—Paclitaxel—ovarian cancer	0.00114	0.00247	CcSEcCtD
Fludrocortisone—Affect lability—Doxorubicin—ovarian cancer	0.00114	0.00247	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CHEK2—ovarian cancer	0.00114	0.00426	CbGpPWpGaD
Fludrocortisone—Hypertension—Paclitaxel—ovarian cancer	0.00114	0.00246	CcSEcCtD
Fludrocortisone—AR—Androgen receptor signaling pathway—CAV1—ovarian cancer	0.00113	0.00423	CbGpPWpGaD
Fludrocortisone—Myalgia—Paclitaxel—ovarian cancer	0.00112	0.00243	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—ovarian cancer	0.00112	0.00419	CbGpPWpGaD
Fludrocortisone—Erythema—Docetaxel—ovarian cancer	0.00112	0.00242	CcSEcCtD
Fludrocortisone—AR—Nongenotropic Androgen signaling—PIK3CA—ovarian cancer	0.00111	0.00418	CbGpPWpGaD
Fludrocortisone—Muscular weakness—Epirubicin—ovarian cancer	0.0011	0.00239	CcSEcCtD
Fludrocortisone—AR—Generic Transcription Pathway—NR5A1—ovarian cancer	0.0011	0.00413	CbGpPWpGaD
Fludrocortisone—NR3C2—Generic Transcription Pathway—PARP1—ovarian cancer	0.0011	0.00412	CbGpPWpGaD
Fludrocortisone—Mood swings—Doxorubicin—ovarian cancer	0.0011	0.00237	CcSEcCtD
Fludrocortisone—Abdominal distension—Epirubicin—ovarian cancer	0.00109	0.00236	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00107	0.00233	CcSEcCtD
Fludrocortisone—Oedema—Paclitaxel—ovarian cancer	0.00107	0.00233	CcSEcCtD
Fludrocortisone—Progesterone—PGR—ovarian cancer	0.00107	0.04	CrCbGaD
Fludrocortisone—Infection—Paclitaxel—ovarian cancer	0.00107	0.00231	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—BRCA1—ovarian cancer	0.00107	0.004	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—GADD45A—ovarian cancer	0.00106	0.00399	CbGpPWpGaD
Fludrocortisone—Pancreatitis—Epirubicin—ovarian cancer	0.00106	0.0023	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00104	0.00225	CcSEcCtD
Fludrocortisone—AR—Nongenotropic Androgen signaling—HRAS—ovarian cancer	0.00103	0.00387	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.00103	0.00387	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—ovarian cancer	0.00103	0.00386	CbGpPWpGaD
Fludrocortisone—Muscular weakness—Doxorubicin—ovarian cancer	0.00102	0.00221	CcSEcCtD
Fludrocortisone—AR—Notch-mediated HES/HEY network—STAT3—ovarian cancer	0.00101	0.0038	CbGpPWpGaD
Fludrocortisone—Abdominal distension—Doxorubicin—ovarian cancer	0.00101	0.00218	CcSEcCtD
Fludrocortisone—Progesterone—CYP1B1—ovarian cancer	0.001	0.0374	CrCbGaD
Fludrocortisone—Headache—Vinorelbine—ovarian cancer	0.001	0.00217	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—ESR1—ovarian cancer	0.000998	0.00374	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—ovarian cancer	0.000991	0.00372	CbGpPWpGaD
Fludrocortisone—NR3C1—Transcription factor regulation in adipogenesis—IL6—ovarian cancer	0.000986	0.0037	CbGpPWpGaD
Fludrocortisone—Dexamethasone—PGR—ovarian cancer	0.000981	0.0366	CrCbGaD
Fludrocortisone—Pancreatitis—Doxorubicin—ovarian cancer	0.00098	0.00212	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000979	0.00212	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Epirubicin—ovarian cancer	0.000975	0.00211	CcSEcCtD
Fludrocortisone—Insomnia—Paclitaxel—ovarian cancer	0.000972	0.00211	CcSEcCtD
Fludrocortisone—Convulsion—Docetaxel—ovarian cancer	0.000967	0.0021	CcSEcCtD
Fludrocortisone—NR3C1—Endoderm Differentiation—APC—ovarian cancer	0.000966	0.00362	CbGpPWpGaD
Fludrocortisone—Hypertension—Docetaxel—ovarian cancer	0.000964	0.00209	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—BRCA2—ovarian cancer	0.000963	0.00361	CbGpPWpGaD
Fludrocortisone—AR—Coregulation of Androgen receptor activity—CCND1—ovarian cancer	0.000953	0.00357	CbGpPWpGaD
Fludrocortisone—Myalgia—Docetaxel—ovarian cancer	0.00095	0.00206	CcSEcCtD
Fludrocortisone—Testosterone—CYP1B1—ovarian cancer	0.000947	0.0354	CrCbGaD
Fludrocortisone—AR—Coregulation of Androgen receptor activity—CTNNB1—ovarian cancer	0.000944	0.00354	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000942	0.00353	CbGpPWpGaD
Fludrocortisone—Dexamethasone—CYP1B1—ovarian cancer	0.000917	0.0342	CrCbGaD
Fludrocortisone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000911	0.00197	CcSEcCtD
Fludrocortisone—Oedema—Docetaxel—ovarian cancer	0.000911	0.00197	CcSEcCtD
Fludrocortisone—AR—Nongenotropic Androgen signaling—AKT1—ovarian cancer	0.000911	0.00342	CbGpPWpGaD
Fludrocortisone—Infection—Docetaxel—ovarian cancer	0.000905	0.00196	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000902	0.00195	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—ovarian cancer	0.000888	0.00333	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000883	0.00331	CbGpPWpGaD
Fludrocortisone—Haemoglobin—Epirubicin—ovarian cancer	0.000869	0.00188	CcSEcCtD
Fludrocortisone—Haemorrhage—Epirubicin—ovarian cancer	0.000865	0.00187	CcSEcCtD
Fludrocortisone—Megestrol acetate—ABCB1—ovarian cancer	0.000855	0.0319	CrCbGaD
Fludrocortisone—Urticaria—Paclitaxel—ovarian cancer	0.000854	0.00185	CcSEcCtD
Fludrocortisone—NR3C1—Generic Transcription Pathway—NR5A1—ovarian cancer	0.000836	0.00313	CbGpPWpGaD
Fludrocortisone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00083	0.0018	CcSEcCtD
Fludrocortisone—Insomnia—Docetaxel—ovarian cancer	0.000824	0.00179	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—ovarian cancer	0.000823	0.00309	CbGpPWpGaD
Fludrocortisone—Haemoglobin—Doxorubicin—ovarian cancer	0.000804	0.00174	CcSEcCtD
Fludrocortisone—Haemorrhage—Doxorubicin—ovarian cancer	0.0008	0.00173	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000798	0.00299	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000792	0.00172	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000773	0.0029	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000773	0.0029	CbGpPWpGaD
Fludrocortisone—Asthenia—Paclitaxel—ovarian cancer	0.000771	0.00167	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—ovarian cancer	0.000767	0.00288	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—ovarian cancer	0.00076	0.00285	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000759	0.00285	CbGpPWpGaD
Fludrocortisone—Erythema—Epirubicin—ovarian cancer	0.000753	0.00163	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—ovarian cancer	0.000745	0.00279	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—WDR77—ovarian cancer	0.000744	0.00279	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—ESR1—ovarian cancer	0.000712	0.00267	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—CCND1—ovarian cancer	0.000704	0.00264	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—CTNNB1—ovarian cancer	0.000697	0.00262	CbGpPWpGaD
Fludrocortisone—Erythema—Doxorubicin—ovarian cancer	0.000697	0.00151	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CXCL8—ovarian cancer	0.000695	0.00261	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—PTEN—ovarian cancer	0.00068	0.00255	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CDKN1B—ovarian cancer	0.000679	0.00255	CbGpPWpGaD
Fludrocortisone—Progesterone—ESR1—ovarian cancer	0.000677	0.0253	CrCbGaD
Fludrocortisone—Vertigo—Epirubicin—ovarian cancer	0.000676	0.00147	CcSEcCtD
Fludrocortisone—Headache—Paclitaxel—ovarian cancer	0.000673	0.00146	CcSEcCtD
Fludrocortisone—Hypersensitivity—Docetaxel—ovarian cancer	0.000671	0.00145	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—IL2—ovarian cancer	0.000664	0.00249	CbGpPWpGaD
Fludrocortisone—NR3C1—Endoderm Differentiation—CTNNB1—ovarian cancer	0.000656	0.00246	CbGpPWpGaD
Fludrocortisone—Methylprednisolone—ABCB1—ovarian cancer	0.000655	0.0245	CrCbGaD
Fludrocortisone—Asthenia—Docetaxel—ovarian cancer	0.000654	0.00142	CcSEcCtD
Fludrocortisone—Convulsion—Epirubicin—ovarian cancer	0.000652	0.00141	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—YAP1—ovarian cancer	0.000652	0.00244	CbGpPWpGaD
Fludrocortisone—Hypertension—Epirubicin—ovarian cancer	0.00065	0.00141	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CCND1—ovarian cancer	0.000647	0.00243	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CTNNB1—ovarian cancer	0.000641	0.0024	CbGpPWpGaD
Fludrocortisone—Myalgia—Epirubicin—ovarian cancer	0.000641	0.00139	CcSEcCtD
Fludrocortisone—NR3C2—Generic Transcription Pathway—ESR1—ovarian cancer	0.000631	0.00237	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—MMP9—ovarian cancer	0.000629	0.00236	CbGpPWpGaD
Fludrocortisone—AR—Generic Transcription Pathway—YAP1—ovarian cancer	0.000628	0.00236	CbGpPWpGaD
Fludrocortisone—Vertigo—Doxorubicin—ovarian cancer	0.000626	0.00136	CcSEcCtD
Fludrocortisone—NR3C1—AP-1 transcription factor network—PTEN—ovarian cancer	0.000625	0.00234	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	0.000619	0.00232	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—ovarian cancer	0.000615	0.00231	CbGpPWpGaD
Fludrocortisone—Oedema—Epirubicin—ovarian cancer	0.000614	0.00133	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000614	0.00133	CcSEcCtD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—ovarian cancer	0.000612	0.0023	CbGpPWpGaD
Fludrocortisone—Infection—Epirubicin—ovarian cancer	0.00061	0.00132	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	0.000609	0.00228	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—STAT3—ovarian cancer	0.000608	0.00228	CbGpPWpGaD
Fludrocortisone—Convulsion—Doxorubicin—ovarian cancer	0.000603	0.00131	CcSEcCtD
Fludrocortisone—Hypertension—Doxorubicin—ovarian cancer	0.000601	0.0013	CcSEcCtD
Fludrocortisone—NR3C1—Adipogenesis—IL6ST—ovarian cancer	0.000599	0.00225	CbGpPWpGaD
Fludrocortisone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000594	0.00129	CcSEcCtD
Fludrocortisone—Myalgia—Doxorubicin—ovarian cancer	0.000593	0.00129	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.00059	0.00221	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—IL2—ovarian cancer	0.000585	0.00219	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—TTF1—ovarian cancer	0.000584	0.00219	CbGpPWpGaD
Fludrocortisone—Headache—Docetaxel—ovarian cancer	0.000571	0.00124	CcSEcCtD
Fludrocortisone—NR3C2—Gene Expression—PGR—ovarian cancer	0.000569	0.00213	CbGpPWpGaD
Fludrocortisone—Oedema—Doxorubicin—ovarian cancer	0.000568	0.00123	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000568	0.00123	CcSEcCtD
Fludrocortisone—Infection—Doxorubicin—ovarian cancer	0.000565	0.00122	CcSEcCtD
Fludrocortisone—NR3C1—Gene Expression—WDR77—ovarian cancer	0.000565	0.00212	CbGpPWpGaD
Fludrocortisone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.00056	0.00121	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000557	0.00209	CbGpPWpGaD
Fludrocortisone—Insomnia—Epirubicin—ovarian cancer	0.000556	0.0012	CcSEcCtD
Fludrocortisone—AR—Androgen receptor signaling pathway—EGFR—ovarian cancer	0.000553	0.00207	CbGpPWpGaD
Fludrocortisone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00055	0.00119	CcSEcCtD
Fludrocortisone—AR—Generic Transcription Pathway—PGR—ovarian cancer	0.000549	0.00206	CbGpPWpGaD
Fludrocortisone—Spironolactone—ABCB1—ovarian cancer	0.000531	0.0198	CrCbGaD
Fludrocortisone—AR—Gene Expression—NR5A1—ovarian cancer	0.00053	0.00199	CbGpPWpGaD
Fludrocortisone—AR—Coregulation of Androgen receptor activity—AKT1—ovarian cancer	0.00053	0.00199	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—PARP1—ovarian cancer	0.000529	0.00198	CbGpPWpGaD
Fludrocortisone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.000522	0.00196	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—MYC—ovarian cancer	0.000519	0.00195	CbGpPWpGaD
Fludrocortisone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000518	0.00112	CcSEcCtD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	0.000515	0.00193	CbGpPWpGaD
Fludrocortisone—Insomnia—Doxorubicin—ovarian cancer	0.000514	0.00111	CcSEcCtD
Fludrocortisone—AR—Generic Transcription Pathway—PARP1—ovarian cancer	0.00051	0.00191	CbGpPWpGaD
Fludrocortisone—Prednisone—ABCB1—ovarian cancer	0.000501	0.0187	CrCbGaD
Fludrocortisone—Urticaria—Epirubicin—ovarian cancer	0.000488	0.00106	CcSEcCtD
Fludrocortisone—AR—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000483	0.00181	CbGpPWpGaD
Fludrocortisone—NR3C1—Generic Transcription Pathway—YAP1—ovarian cancer	0.000477	0.00179	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	0.000474	0.00178	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—ovarian cancer	0.00047	0.00176	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	0.000462	0.00173	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000462	0.00173	CbGpPWpGaD
Fludrocortisone—Prednisolone—ABCB1—ovarian cancer	0.000462	0.0172	CrCbGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	0.000461	0.00173	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	0.000457	0.00171	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Epirubicin—ovarian cancer	0.000453	0.000981	CcSEcCtD
Fludrocortisone—Betamethasone—ABCB1—ovarian cancer	0.000452	0.0169	CrCbGaD
Fludrocortisone—Urticaria—Doxorubicin—ovarian cancer	0.000452	0.000979	CcSEcCtD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—MAPK1—ovarian cancer	0.000448	0.00168	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	0.000445	0.00167	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000445	0.00167	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—TTF1—ovarian cancer	0.000443	0.00166	CbGpPWpGaD
Fludrocortisone—Asthenia—Epirubicin—ovarian cancer	0.000441	0.000955	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000433	0.00162	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—PPP2R1A—ovarian cancer	0.000429	0.00161	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—TP53—ovarian cancer	0.000427	0.0016	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	0.000422	0.00158	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000419	0.000908	CcSEcCtD
Fludrocortisone—NR3C1—Generic Transcription Pathway—PGR—ovarian cancer	0.000416	0.00156	CbGpPWpGaD
Fludrocortisone—Asthenia—Doxorubicin—ovarian cancer	0.000408	0.000884	CcSEcCtD
Fludrocortisone—NR3C1—Gene Expression—NR5A1—ovarian cancer	0.000402	0.00151	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	0.000402	0.00151	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000401	0.0015	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000393	0.00147	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000392	0.00147	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—AKT1—ovarian cancer	0.000392	0.00147	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—CTNNB1—ovarian cancer	0.000391	0.00147	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—IL6—ovarian cancer	0.00039	0.00146	CbGpPWpGaD
Fludrocortisone—NR3C1—Generic Transcription Pathway—PARP1—ovarian cancer	0.000387	0.00145	CbGpPWpGaD
Fludrocortisone—Headache—Epirubicin—ovarian cancer	0.000385	0.000834	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000382	0.00143	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000379	0.00142	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—TP53—ovarian cancer	0.000376	0.00141	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MYC—ovarian cancer	0.00037	0.00139	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000369	0.00138	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000366	0.00137	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	0.000362	0.00136	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	0.000362	0.00136	CbGpPWpGaD
Fludrocortisone—Headache—Doxorubicin—ovarian cancer	0.000356	0.000772	CcSEcCtD
Fludrocortisone—Hydrocortisone—ABCB1—ovarian cancer	0.000353	0.0132	CrCbGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.00035	0.00131	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—IL6—ovarian cancer	0.000344	0.00129	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	0.000342	0.00128	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—STAT3—ovarian cancer	0.000341	0.00128	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000338	0.00127	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.000333	0.00125	CbGpPWpGaD
Fludrocortisone—NR3C2—Generic Transcription Pathway—MYC—ovarian cancer	0.000328	0.00123	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	0.00032	0.0012	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—ovarian cancer	0.000317	0.00119	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000315	0.00118	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000307	0.00115	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—TP53—ovarian cancer	0.000304	0.00114	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—ESR1—ovarian cancer	0.000304	0.00114	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—YAP1—ovarian cancer	0.000302	0.00113	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.0003	0.00113	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.0003	0.00113	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000297	0.00112	CbGpPWpGaD
Fludrocortisone—AR—Generic Transcription Pathway—ESR1—ovarian cancer	0.000293	0.0011	CbGpPWpGaD
Fludrocortisone—Progesterone—ABCB1—ovarian cancer	0.000288	0.0107	CrCbGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000283	0.00106	CbGpPWpGaD
Fludrocortisone—Testosterone—ABCB1—ovarian cancer	0.000272	0.0102	CrCbGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000271	0.00102	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—PGR—ovarian cancer	0.000264	0.00099	CbGpPWpGaD
Fludrocortisone—Dexamethasone—ABCB1—ovarian cancer	0.000263	0.00982	CrCbGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.00026	0.000976	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	0.000257	0.000963	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	0.000252	0.000945	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—PARP1—ovarian cancer	0.000246	0.000921	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—IL6—ovarian cancer	0.000238	0.000892	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—YAP1—ovarian cancer	0.000229	0.000861	CbGpPWpGaD
Fludrocortisone—NR3C1—Generic Transcription Pathway—ESR1—ovarian cancer	0.000222	0.000833	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	0.000213	0.000798	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000206	0.000771	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—PGR—ovarian cancer	0.0002	0.000751	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—PPP2R1A—ovarian cancer	0.000199	0.000747	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—PARP1—ovarian cancer	0.000186	0.000699	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—MAPK3—ovarian cancer	0.000163	0.00061	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—MYC—ovarian cancer	0.000158	0.000593	CbGpPWpGaD
Fludrocortisone—AR—Generic Transcription Pathway—MYC—ovarian cancer	0.000152	0.000571	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—PPP2R1A—ovarian cancer	0.000151	0.000567	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—ESR1—ovarian cancer	0.000141	0.000529	CbGpPWpGaD
Fludrocortisone—NR3C1—Generic Transcription Pathway—MYC—ovarian cancer	0.000116	0.000433	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—AKT1—ovarian cancer	0.00011	0.000411	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—ESR1—ovarian cancer	0.000107	0.000401	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—MAPK3—ovarian cancer	7.54e-05	0.000283	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—MYC—ovarian cancer	7.33e-05	0.000275	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—MAPK3—ovarian cancer	5.72e-05	0.000215	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—MYC—ovarian cancer	5.56e-05	0.000209	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—AKT1—ovarian cancer	5.09e-05	0.000191	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—AKT1—ovarian cancer	3.86e-05	0.000145	CbGpPWpGaD
